Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). Its core function is to stimulate the pituitary gland to release growth hormone (GH) in a physiological pulsatile manner by mimicking the body's endogenous GHRH, thereby increasing levels of insulin-like growth factor-1 (IGF-1).
It is important to note that Tesamorelin is a prescription drug that received FDA approval in 2010 for the treatment of HIV-associated lipodystrophy. It remains the only approved medication specifically indicated for reducing visceral adipose tissue (VAT) in this patient population.
Core Clinical Effect: Reduction of Visceral Adiposity
For patients with HIV-associated lipodystrophy, Tesamorelin is one of the most effective targeted therapies available:
Significant Reduction in Visceral Fat: Multiple clinical trials have confirmed that Tesamorelin effectively reduces intra-abdominal visceral adipose tissue (VAT). A meta-analysis encompassing five randomized controlled trials demonstrated a mean reduction in visceral fat area of approximately 27.71 cm². Similar positive effects have also been observed in studies involving patients on the latest antiretroviral regimens.
Improved Body Composition: While reducing truncal fat and waist circumference, Tesamorelin concurrently promotes a moderate increase in lean body mass (including muscle) , averaging approximately 1.42 kg – achieving a favorable body composition重塑 (remodeling).
Investigational and Emerging Applications
Researchers are also exploring Tesamorelin's potential in other metabolic conditions; however, these applications remain largely off-label or at the investigational stage:
Reduction of Hepatic Fat: Studies indicate that Tesamorelin effectively reduces liver fat content. A study focusing on HIV-associated non-alcoholic fatty liver disease (NAFLD) found that it also downregulates gene expression related to inflammation and tissue repair. Currently, a Phase II clinical trial is underway to further evaluate its efficacy in a broader population with fatty liver disease.
Improvement in Metabolic Parameters: Some studies have observed impro